Fair value (multi-method)
Four independent methods triangulate what VRTX is worth. The headline is the Forward-DCF intrinsic value at a normalized growth rate; the margin of safety compares it to the current price.
Estimated fair value (Forward DCF)
$770.70
Method range
$83.42 – $770.70
median $492.79
Valuation methods
Each method’s implied fair value per share and its upside versus the current price. Missing methods (no analyst coverage, negative earnings, etc.) are shown as “—”.
| Method | Fair value | Upside vs price |
|---|---|---|
| Forward DCF | $770.70 | +63.09% |
| Exit multiple | $437.64 | -7.39% |
| Analyst target | $547.93 | +15.95% |
| Graham number | $83.42 | -82.35% |
- Forward DCF$770.70
- Exit multiple$437.64
- Analyst target$547.93
- Graham number$83.42
Stock price
$472.57
FCF / share (TTM)
$5.10
3Y FCF CAGR
7.5%
Fair value @ hist. growth
$218.40
This analysis is for informational purposes only and is not financial advice. Scenario prices and DCF-style figures depend on your assumptions and data from public filings and estimates. They are not forecasts of future returns.
Implied FCF growth
17.0%
per year over your projection horizon
Margin of safety -116.4% vs hist-growth DCF
Historical 3Y CAGR
7.5%
Your model implies
17.0%
Analyst consensus is EPS-only — no comparable FCF / share estimate to show on this basis.
Model inputs
Move sliders to test how the reverse DCF reacts. Historical-growth markers show where the company has actually grown over the last cycle.
Undiscounted FCF per share over 10 years at 8% annual growth.
Sensitivity — implied growth vs your assumptions
Each cell shows the per-share growth rate the market would need to justify the current price at that combination of discount rate (rows) and terminal growth (columns). Your selected inputs are highlighted.
| Row axis: discount rate. Column axis: terminal growth.Terminal g →↓ Discount | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 5.0% | 15.5% | 13.9% | 12.0% | 9.7% | 6.8% |
| 5.1% | 16.0% | 14.5% | 12.7% | 10.5% | 7.8% |
| 6.1% | 19.6% | 18.4% | 17.0% | 15.5% | 13.6% |
| 7.1% | 22.7% | 21.7% | 20.6% | 19.4% | 18.0% |
| 8.1% | 25.5% | 24.7% | 23.7% | 22.7% | 21.6% |
Historical multiples
Each bar is the trailing five-year range (low left, high right). Filled portion runs from low to today; the dot marks today; the small tick marks the five-year median. Low, median, and high are listed under each bar.
Net cash
$1.21B
Total debt − cash
Beta
0.29
Vs market benchmark
Frequently asked questions
Vertex Pharmaceuticals (VRTX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.